BIOQUAL (OTCMKTS:BIOQ) and Icon (NASDAQ:ICLR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations for BIOQUAL and Icon, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIOQUAL 0 0 0 0 N/A
Icon 1 1 6 0 2.63

Icon has a consensus price target of $146.13, indicating a potential upside of 2.93%. Given Icon’s higher possible upside, analysts clearly believe Icon is more favorable than BIOQUAL.


This table compares BIOQUAL and Icon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Icon 12.88% 26.08% 14.62%

Insider & Institutional Ownership

86.5% of Icon shares are held by institutional investors. 39.2% of BIOQUAL shares are held by company insiders. Comparatively, 44.0% of Icon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BIOQUAL and Icon’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIOQUAL $35.88 million 0.92 $3.66 million N/A N/A
Icon $1.76 billion 4.37 $281.48 million $5.39 26.34

Icon has higher revenue and earnings than BIOQUAL.

Volatility & Risk

BIOQUAL has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Icon has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.


BIOQUAL pays an annual dividend of $0.60 per share and has a dividend yield of 1.6%. Icon does not pay a dividend.


Icon beats BIOQUAL on 12 of the 13 factors compared between the two stocks.


Bioqual, Inc. provides research, development, consulting, and testing/assay services to commercial clients and government laboratories in the United States. The company provides research services in the areas of cancer, AIDS, hepatitis, influenza, immunology, transgenic, contraception, breeding and development of genetically defined animals, and neurobiology and behavior, as well as zika, dengue, malaria, respiratory syncytial virus, and other infectious diseases. Its services also include sample processing, virus stock generation, infectious virus quantitation, virus neutralization assays, hemagglutination inhibition assays, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides in-vivo animal model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive News & Ratings for BIOQUAL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOQUAL and related companies with's FREE daily email newsletter.